Pharmafile Logo
Pharmafocus logo
Advanced Search

Stelara

Showing 15 posts of 25 posts found.

janssen_latest_logo_on_sign

FDA expands Stelara indication to cover paediatric plaque psoriasis

July 31, 2020
Medical Communications, Sales and Marketing Janssen, Stelara, pharma, plaque psoriasis

Janssen’s IL-12 and IL-23 inhibitor Stelara (ustekinumab) has had its approved indications expanded by the FDA to include the treatment …

News
janssen_latest_logo_on_sign_closer

NICE backtracks to approve Janssen’s Stelara in ulcerative colitis

April 28, 2020
Manufacturing and Production, Research and Development Janssen, NICE, Stelara, ulcerative colitis

NICE has recommended Janssen’s Stelara (ustekinumab) for the treatment of moderately to severely active ulcerative colitis (UC), a move which …

News
nhs_sign_8

Scottish Medicines Consortium approves new drugs in multiple sclerosis, ulcerative colitis and diabetes

April 15, 2020
Research and Development, Sales and Marketing Biogen, Fambyra, Janssen, NHS, Rimzoic, Sandoz, Sanofi, Scotland, Scottish Medicines Consortium, Stelara, Suliqua, pharma

Medical regulation must still continue even in a global pandemic, and the Scottish Medicines Consortium, (SMC) has ploughed on with …

News
janssen_latest_logo_on_sign_closer

Janssen shows off Phase 3b interim data for Stelara in Crohn’s disease

February 18, 2020
Manufacturing and Production, Research and Development Crohn’s disease, Janssen, Stelara, crohn's disease, pharma

Janssen has revealed new interim Phase 3b data from a study investigating the efficacy of Stelara (ustekinumab) in the treatment …

News
janssen_latest_logo_on_sign_closer

European Commission expands Stelara for paediatric moderate to severe plaque psoriasis

January 24, 2020
Research and Development Europe, Janssen, Stelara, pharma

Janssen’s Stelara (ustekinumab) has seen its label expanded in Europe to include the treatment of moderate to severe plaque psoriasis …

News

UCB’s bimekizumab meets primary and secondary endpoints, beating Janssen’s Stelara in chronic plaque psoriasis

October 17, 2019
Research and Development Stelara, UCB Pharma, bimekizumab, pharma, plaque psoriasis

UCB Pharma has announced new data from the first of three Phase 3 studies investigating the efficacy of its IL-17A …

News
janssen_latest_logo_on_sign_closer

Janssen’s Stelara becomes first European-approved biologic IL-12/IL-23 inhibitor for ulcerative colitis

September 5, 2019
Sales and Marketing Europe, Janssen, Stelara, pharma, ulcerative colitis

Janssen has announced that its therapy Stelara (ustekinumab) hass secured a label expansion from the European Commission, approving the drug …

News
janssen_latest_logo_on_sign_closer

Janssen’s ulcerative colitis treatment shows positive results in phase 3 trials

March 13, 2019
Manufacturing and Production, Research and Development Jansenn, Stelara, phase 3 trials, ulcerative colitis

Janssen’s ulcerative colitis treatment, Stelara (ustekinumab subcutaneous) has shown positive results as maintenance therapy in phase 3 trials. The study …

News
novartis_side_building

Novartis’ Cosentyx tops Janssen’s Stelara in moderate-to-severe psoriasis trial

March 5, 2019
Manufacturing and Production, Research and Development Cosentyx, Janssen, Novartis, Stelara, pharma, psoriasis

New data has been revealed in support of Novartis’ Cosentyx (secukinumab) in the treatment of moderate-to-severe plaque psoriasis, demonstrating the …

News
shutterstock_512649

J&J joins in on industry price hiking; almost 500 drug prices increased in 2019 so far

January 11, 2019
Medical Communications, Sales and Marketing J&J, JJ, Stelara, US, Xarelto, Zytiga, pharma, price hikes

It’s only the second week of the New Year, and Johnson & Johnson has announced plans to hike the prices …

News
janssen_latest_logo_on_sign_closer

Janssen’s Stelara shows promise across two dosages in ulcerative colitis

October 9, 2018
Manufacturing and Production, Research and Development Janssen, Stelara, pharma, ulcerative colitis

Janssen’s biologic therapy Stelara (ustekinumab) has shown new efficacy in the treatment of moderate to severe ulcerative colitis in two …

News
novartis_outside_1

Novartis debuts new data showing Cosentyx’s superiority over Janssen’s Stelara in psoriasis

January 16, 2018
Manufacturing and Production, Research and Development Cosentyx, Janssen, Novartis, Stelara, pharma

Novartis has lifted the curtain on new data comparing the efficacy of Cosentyx (secukinumab) to Janssen’s Stelara (ustekinumab) in achieving …

News
janssen_latest_logo_on_sign_closer

Janssen’s Stelara shows improvement in Crohn’s symptoms within one week, new findings reveal

October 30, 2017
Manufacturing and Production, Research and Development Crohn’s disease, Janssen, Stelara, crohn's disease, pharma

Janssen has unveiled new data on Stelara (ustekinumab) in the treatment of patients with moderately to severely active Crohn’s disease …

News
janssen_latest_logo_on_sign

FDA expands Janssen’s Stelara to cover adolescent psoriasis patients

October 16, 2017
Sales and Marketing FDA, Janssen, Stelara, pharma, psoriasis

Janssen has announced that the FDA has approved an expanded indication for its psoriasis therapy Stelara (ustekinumab) for the treatment …

News

NICE recommends Janssen’s first-of-its-kind Crohn’s drug Stelara

May 3, 2017
Research and Development, Sales and Marketing Crohn’s disease, Janssen, NICE, Stelara, crohn's disease

Janssen has announced that it has secured recommendation from NICE for Stelara (ustekinumab) in the indication of moderately to severely …

News

Latest content

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

April 24, 2024

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024